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cultured anaerobically. C. difﬁcile was detected in nine (6.4%) of 141 (95% conﬁdence interval 4.2–13.1), of which seven (77.8%) were from
children. HIV infection, prolonged hospitalization and antibiotic use were independent factors associated with the occurrence of C. difﬁcile in
the gastrointestinal tract. Two of the toxigenic isolates were typed as ribotype 045, and the other two had unknown ribotype. All C. difﬁcile
isolates were susceptible to metronidazole, moxiﬂoxacin and clarithromycin, while three isolates were resistant to clarithromycin. C. difﬁcile
may be an important pathogen causing diarrhoea in sub-Saharan Africa among immunocompromised patients.
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E-mail: mshana72@yahoo.comIntroductionClostridium difﬁcile is considered to be among the normal ﬂora of
the gastrointestinal tract. It mainly becomes pathogenic if the
normal intestinal ﬂora is disturbed. The use of antibiotics has
been identiﬁed as the major risk factor for C. difﬁcile infection in
high-income countries [1]. Few studies on C. difﬁcile prevalence
exist from sub-Saharan Africa [2–6]; a prevalence of gastroin-
testinal carriage of up to 43% has been reported in one these
studies. Outcome of C. difﬁcile presence in gastrointestinal tract
can range from asymptomatic colonization to a severe toxic
megacolon with bowel perforation and sepsis [1]. In Tanzania,New Microbes and New Infections © 2015 The Authors. Published by El
This is an open access artino studies have been performed to investigate prevalence of
C. difﬁcile–associated diarrhoea; therefore, for the ﬁrst time we
report the occurrence and associated factors of C. difﬁcile
among adults and children attending Sekou Toure and Bugando
Medical Centre in Mwanza, Tanzania. We also report the
toxigenic strain with unknown ribotype.MethodsThis was a hospital-based comparative cross-sectional study
conducted between August and October 2014 at Bugando
Medical Centre, a tertiary-care hospital, and Sekou Toure
regional hospital in Mwanza, Tanzania. All patients with diar-
rhoea attending these hospitals were eligible to participate in
the study. All patients with diarrhoea admitted in paediatric and
medical wards during the study period were enrolled unless
they failed to consent/assent. Randomly, 109 adult relativesNew Microbe and New Infect 2015; 8: 99–102
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screened as control subjects for the presence of C. difﬁcile. A
standardized questionnaire was used to collect social de-
mographic and clinical data, including HIV status, duration of
hospitalization and history of antibiotic use and animal keeping.
Fresh stool samples from patients with and without diar-
rhoea were collected and processed within 4 hours. Culture
was done on chromogenic agar (CHROMagar, Paris France)
supplemented with CHROMagar supplements for C. difﬁcile.
Watery stools were plated directly, while stools from the
control group were diluted with phosphate-buffered saline as
previously described [7]. Plates were incubated anaerobically
for 24 hours; anaerobic condition was achieved using an
anaerobic gas pack (bioMérieux, Marcy l’Etoile, France).
C. difﬁcile isolates were tested for the glutamate dehydrogenase
and C. difﬁcile toxins A and B using rapid commercial tests (Quik
Chek Complete, Alere Techlab, Blacksburg, VA, USA) [8]. The
conﬁrmation of the toxin production was done using multiplex
PCR to detect toxin gene proﬁle (German Reference Labora-
tory for C. difﬁcile, Homburg/Saar) [9].
Susceptibility testing to metronidazole, clarithromycin, van-
comycin and moxiﬂoxacin was performed by Etest test (BMD,
Marne-la-Vallée, France) following the manufacturer’s guide-
lines, and European Committee on Antimicrobial Susceptibility
Testing break points were used to interpret the results. Con-
trol strain ATCC 700057 (German Reference Laboratory for
C. difﬁcile, Homburg/Saar) was included to verify the repro-
ducibility of the test. PCR ribotyping was performed according
to standard protocols using capillary gel electrophoresis [10].
Data were entered in the computer using Excel (Microsoft,
Redmond, WA, USA) and analysed by Stata 11 (StataCorp,
College Station, TX). Continuous variables (age and duration of
hospitalization) were summarized as medians, while categorical
variables were summarized as proportions. The Wilcoxon rank
sum (Mann-Whitney) test was performed to compare the
medians of the two groups. Univariate and multivariate logistic
regression analyses were done to determine the association of
different factors with positive C. difﬁcile culture. A p value of less
0.05 was considered to indicate a statistically signiﬁcant
difference.
The protocol to perform this study was approved by
Bugando Medical Centre/Catholic University of Health and
Allied Sciences ethics review committee, and all participants or
caretakers signed informed consent.ResultsA total of 250 participants were investigated in this study. Of
250 participants; 141 (56%) had diarrhoea and 110 (44%) hadNew Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceno diarrhoea. Of 141 participants with diarrhoea, 69 (48.9%)
were  12 years of age. The age of participants with diarrhoea
ranged from 1 month to 65 years old, with a median age of 13
months (interquartile range (IQR) 8–60 months). Female sub-
jects (82, 58.2%) formed the majority of participants. Most of
participants without diarrhoea were adults with a mean age of
35 ± 4 years. All participants with diarrhoea were hospitalized
at the time of enrollment. The median duration of hospitaliza-
tion was 12 hours (IQR, 7–24 hours).
C. difﬁcile was cultured from nine (6.4%) of 141 (95% con-
ﬁdence interval, 4.2–13.1) patients with diarrhoea, while none
of the stool samples from 109 relatives without diarrhoea was
positive. Out of seven isolates from children, six were found to
be toxigenic (toxin A and B).
All nine patients who were found to carry C. difﬁcile reported
that they had used antibiotics previously. In addition, a total of
eight (12.7%) of 63 HIV-positive individuals were found to be
infected by C. difﬁcile compared to only one (1.3%) of 78 among
HIV-negative individuals (odds ratio, 33; 95% conﬁdence in-
terval, 3–370; p 0.004) (Table 1). Also, it was observed that
participants from Bugando Medical Centre were signiﬁcantly
more infected by C. difﬁcile than those from Sekou Toure
(15.4% vs. 1.1%, p 0.002) (Table 1). The median duration of
hospitalization of patients who were culture positive for
C. difﬁcile was 48 hours (IQR, 36–72 hours) compared to 12
hours (IQR, 6.5–24 hours) of those with negative stool culture
for C. difﬁcile (p 0.0028).
Seven isolates (four toxigenic and three nontoxigenic strains)
were available for ribotyping, multiplex PCR for toxin genes and
susceptibility testing. Ribotype 038 was detected in all non-
toxigenic strains. Toxigenic 045 ribotype isolates (n = 2) were
positive for toxin A, B and for binary toxin genes (tcdA, tcdB)
while the two other toxigenic strains were positive for toxin A
and B genes (tcdA, tcdB). However, PCR ribotype of both iso-
lates remained undetermined by comparison to institutional
data bank proﬁles. One of the two strains with unknown
ribotype close similarity to ribotype 228 and 043 was noted,
while the second strain showed similarity to ribotype 035 ac-
cording to ribotype fragment length proﬁles. All seven isolates
were sensitive to vancomycin, moxiﬂoxacin and metronidazole
(Table 2), with three isolates being resistant to clarithromycin.DiscussionC. difﬁcile in high-income countries is one of the most important
causes of health care–associated infections [11–13]. In recent
decades, an increase of incidence, morbidity and mortality
related to C. difﬁcile infection has been reported in high-income
countries, such as the United States and Canada as well asEuropean Society of Clinical Microbiology and Infectious Diseases, NMNI, 8, 99–102
nses/by-nc-nd/4.0/)
TABLE 1. Factors associated with Clostridium difﬁcile infections among 141 participants with diarrhoea
C. difﬁcile + VE Univariate analysis Multivariate analysis
Characteristic (n) n (%) OR (95% CI) p OR (95% CI) p
Duration of hospitalization (hours) 48 (IQR, 36–72) 1.04 (1.01–1.07) 0.001 23.6 (1.2–453) 0.036
Age
Adults (33) 3 (9.1) 1
Children (108) 6 (5.7) 0.588 (0.13–2.5) 0.781 0.998 (0.994–1.00) 0.539
Hospital
Sekou Toure (84) 1 (1.2) 1
BMC (57) 8 (14.4) 13.5 (1.6–111) 0.015 10.9 (1.02–117) 0.047
HIV status
Negative (114) 1 (0.88) 1
Positive (27) 8 (29.6) 47 (5.62–402) <0.001 33 (3–370) 0.004
Animal keeping
No (93) 6 (6.4) 1
Yes (48) 3 (6.2) 0.96 (0.23–4.4) 0.963 0.91 (0.12–6.4) 0.927
BMC, Bugando Medical Centre; CI, conﬁdence interval; IQR, interquartile range; OR, odds ratio.
TABLE 2. Characteristics of seven isolates available for ribotyping
Strain Subject Ribotype ToxA ToxB Binary toxin CL RIF MET MF VA
T3 Child Unknown Positive Positive Negative S S S S S
T91 Child Unknown Positive Positive Negative S S S S S
T108 Adult O38 Negative Negative Negative R R S S S
T103 Adult O38 Negative Negative Negative R S S S S
T18 Child O38 Negative Negative Negative R S S S S
T15 Child O45 Positive Positive Positive S S S S S
T22 Child O45 Positive Positive Positive S S S S S
CL, clarithromycin; MET, metronidazole; MF, moxiﬂoxacin; ND, not done; R, resistant; RIF, rifampicin; S, sensitive; VA, vancomycin.
ToxA and ToxB: C. difﬁcile toxins A and B.
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antibiotics in treatment of diarrhoeal diseases in Tanzania and in
other African countries [15,16], there is limited data regarding
C. difﬁcile infections in sub-Saharan Africa.
The prevalence rate of C. difﬁcile infection/carriage in sub-
Saharan Africa has been reported to range from 4% to 43%
[2,3,17]. In Zimbabwe, a prevalence rate of C. difﬁcile infection
of 8.6% was observed [17], which is almost similar to the
prevalence in this study. As observed in previous studies
[14,18], no signiﬁcant difference was observed between chil-
dren and adults regarding infection/carriage rates; however, the
high-risk group of adults aged > 65 years was missing in this
study. In this study, no statistically signiﬁcant difference was
observed for the occurrence of C. difﬁcile between children and
adults [19].
It was observed that HIV-infected individuals were signiﬁ-
cantly more positive for C. difﬁcile than those without HIV
infection. This was previously observed in Nigeria in adults [3].
Also, we observed more carriage in malnourished children, and
of two infected adults, one was HIV positive and the other had
diabetes. It is therefore possible that C. difﬁcile infections may be
underappreciated among immunocompromised patients in Af-
rica as a result of limited diagnostic facilities.
Another important ﬁnding in this study is detection of more
cases in a tertiary-care hospital than a regional hospital. ThisNew Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on behal
This is an open access articould be explained by the fact that patients admitted to tertiary-
care hospitals have received broad-spectrum antibiotic treat-
ment for a longer time than those at regional hospitals [15]. As
documented previously [1] and in this study, prolonged anti-
biotic use has been found to be an important risk factor for
C. difﬁcile infections.
The toxigenic ribotype 045 detected in this study has been
detected mainly from animals such as pigs [20,21]. The detec-
tion of ribotype 045 in humans and unknown ribotype in seven
isolates requires more studies to investigate the epidemiology
of C. difﬁcile infections in Africa.
In this study, because the aim was to detect C. difﬁcile in-
fections by culture, the toxin was assayed from colonies, not
from stool specimens; this may have underestimated the
magnitude of participants with positive C. difﬁcile toxins. In
addition, other enteric pathogens were not investigated;
therefore, it is difﬁcult for us to conclude whether C. difﬁcile
was the cause of diarrhoea, especially in children.
C. difﬁcile may be an underappreciated pathogen causing
diarrhoea among HIV-infected children on prolonging antibiotic
treatment in Africa. Improvements in clinical microbiology
services in Africa are needed to be able to diagnose C. difﬁcile
infections. Also, a large study to investigate the epidemiology of
C. difﬁcile in Africa is warranted on the basis of the fact that its
epidemiology may not be the same as in developed countries.f of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 8, 99–102
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